Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXtm (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain.

Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

Explore how chemotherapy causes peripheral neuropathy in 40% of cancer patients. Learn about the risk factors and the need ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new evidence review ...